Advanced search
Publication Cover
Current Medical Research and Opinion Volume 36, 2020 - Issue 10
Submit an article Journal homepage
3,984
Views
11
CrossRef citations to date
0
Altmetric
Oncology

Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer

Kiyotaka Yoha Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, JapanCorrespondence[email protected]
,
Shinji Atagib Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
,
Martin Reckc Lungen Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany
,
Edward B. Garond David Geffen School of Medicine, University of California Los Angeles/TRIO-US Network, Los Angeles, CA, USA
,
Santiago Ponce Aixe Hospital Universitario, CNIO Lung Cancer Clinical Research Unit, Universidad Complutense and Ciberonc, Madrid, Spain
,
Denis Moro-Sibilotf Grenoble University Hospital, Grenoble, France
,
Katherine B. Winfreeg Eli Lilly and Company, Indianapolis, IN, USA
,
Bente Frimodt-Mollerh Eli Lilly and Company, Copenhagen, Denmark
,
Annamaria Zimmermanng Eli Lilly and Company, Indianapolis, IN, USA
,
Carla Visseren-Gruli Lilly Oncology, Utrecht, Netherlands
,
Kazuhiko Nakagawaj Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan
& for the RELAY investigators show all
Pages 1667-1675 | Received 30 Apr 2020, Accepted 08 Aug 2020, Published online: 28 Aug 2020

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Maxime Boussageon, Aurélie Swalduz & Maurice Pérol. (2021) The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer. Expert Review of Anticancer Therapy 21:10, pages 1071-1080.
Read now

Articles from other publishers (10)

Cliff Molife, Katherine B. Winfree, Hollie Bailey, Yulia D’yachkova, Cameron Forshaw, Sangmi Kim, Kaisa-Leena Taipale & Tarun Puri. (2023) Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study. Advances in Therapy 40:7, pages 3135-3168.
Crossref
Mohan Liu, Kaiwen Xiao & Li Yang. (2023) EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis. International Immunopharmacology 119, pages 110001.
Crossref
Jasna Deluce, David Maj, Saurav Verma, Daniel Breadner, Gabriel Boldt & Jacques Raphael. (2023) Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non–small Cell Lung Cancer Harboring Activating EGFR Mutations. American Journal of Clinical Oncology Publish Ahead of Print.
Crossref
Kazuhiko Nakagawa, Edward B. Garon, Ling Gao, Sophie Callies, Annamaria Zimmermann, Richard Walgren, Carla Visseren-Grul & Martin Reck. (2022) RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship. Cancer Chemotherapy and Pharmacology 90:2, pages 137-148.
Crossref
Ernest Nadal, Hidehito Horinouchi, Jin-Yuan Shih, Kazuhiko Nakagawa, Martin Reck, Edward B. Garon, Yu-Feng Wei, Jens Kollmeier, Bente Frimodt-Moller, Emily Barrett, Olga Lipkovich, Carla Visseren-Grul & Silvia Novello. (2021) RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. Drug Safety 45:1, pages 45-64.
Crossref
Sara Moore & Paul Wheatley-Price. (2021) EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC. Journal of Thoracic Oncology 16:11, pages 1788-1792.
Crossref
Hongyun Zhao, Wenxiu Yao, Xuhong Min, Kangsheng Gu, Guohua Yu, Zhonghan Zhang, Jiuwei Cui, Liyun Miao, Li Zhang, Xia Yuan, Yong Fang, Xiuhua Fu, Chengping Hu, Xiaoli Zhu, Yun Fan, Qitao Yu, Gang Wu, Ou Jiang, Xiuping Du, Jiwei Liu, Wei Gu, Zhiguo Hou, Quanren Wang, Rongrong Zheng, Xianfeng Zhou & Li Zhang. (2021) Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). Journal of Thoracic Oncology 16:9, pages 1533-1546.
Crossref
E. I. Borisova & S. L. Gutorov. (2021) Erlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation. Meditsinskiy sovet = Medical Council:9, pages 42-47.
Crossref
Xiuning Le, Monique Nilsson, Jonathan Goldman, Martin Reck, Kazuhiko Nakagawa, Terafumi Kato, Luis Paz Ares, Bente Frimodt-Moller, Katharina Wolff, Carla Visseren-Grul, John V. Heymach & Edward B. Garon. (2021) Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. Journal of Thoracic Oncology 16:2, pages 205-215.
Crossref
Giuliano Palumbo, Giovanna Giovanna Esposito, Guido Carillio, Anna Manzo, Agnese Montanino, Vincenzo Sforza, Raffaele Costanzo, Claudia Sandomenico, Carmine La Manna, Nicola Martucci, Antonello La Rocca, Giuseppe De Luca, Maria Carmela Piccirillo, Rossella De Cecio, Francesco Perrone, Giuseppe Totaro, Paolo Muto, Carmine Picone, Nicola Normanno & Alessandro Morabito. (2020) Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer. Exploration of Targeted Anti-tumor Therapy 1:2, pages 117-130.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.